GlassScriptPhysician profile
Yvonne Y Chen
NPI 1306959135
$11,249.54
in general payments reported to CMS, 2019-2025
27 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $365 · 2021: $790 · 2022: $798 · 2023: $2,271 · 2024: $4,693 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,923 · Consulting Fee: $2,984 · Education: $84.21 · Travel and Lodging: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,923.29 |
| Consulting Fee | $2,983.75 |
| Education | $84.21 |
| Travel and Lodging | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,313.10 | 2022-2025 | Jynarque |
| Otsuka America Pharmaceutical, INC. | $1,268.66 | 2020-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $1,091.63 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $817.91 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Amgen INC. | $591.43 | 2020-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $559.64 | 2022-2025 | |
| Genzyme Corporation | $425.47 | 2021-2023 | |
| Lilly USA, LLC | $335.48 | 2023-2025 | Jardiance, Mounjaro |
| Vifor Pharma, INC. | $291.47 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $276.85 | 2024-2025 | Acthar |
| Novo Nordisk INC | $262.54 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.30 | 2021-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $230.73 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $206.21 | 2023-2024 | |
| Glaxosmithkline, LLC. | $192.28 | 2022-2024 | Arexvy, Benlysta, Jesduvroq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $184.97 | 2022-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $166.60 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $152.98 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $146.51 | 2019-2023 | Ultomiris |
| Opko Pharmaceuticals, LLC | $100.92 | 2022-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $96.94 | 2023-2024 | Lupkynis |
| Ardelyx, INC. | $86.82 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $62.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $43.62 | 2019 | |
| Akebia Therapeutics INC | $38.92 | 2020 | |
| Apellis Pharmaceuticals, INC. | $26.72 | 2025 | Empaveli |
| Nxstage Medical, INC. | $24.94 | 2025 | Liberty Select Cycler, Nxstage System One |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvonne Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.